Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network.
Fiche publication
Date publication
juillet 2019
Journal
Neuro-oncology practice
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TAILLANDIER Luc
Tous les auteurs :
Darlix A, Mandonnet E, Freyschlag CF, Pinggera D, Forster MT, Voss M, Steinbach J, Loughrey C, Goodden J, Banna G, Di Blasi C, Foroglou N, Hottinger AF, Baron MH, Pallud J, Duffau H, Rutten GJ, Almairac F, Fontaine D, Taillandier L, Pessanha Viegas C, Albuquerque L, von Campe G, Urbanic-Purkart T, Blonski M
Lien Pubmed
Résumé
Diffuse low-grade gliomas (DLGGs) are rare and incurable tumors. Whereas maximal safe, functional-based surgical resection is the first-line treatment, the timing and choice of further treatments (chemotherapy, radiation therapy, or combined treatments) remain controversial.
Mots clés
PCV, chemotherapy, clinical practice, diffuse low-grade glioma, temozolomide
Référence
Neurooncol Pract. 2019 Jul;6(4):264-273